|Bid||0.6900 x 2000|
|Ask||0.7300 x 400|
|Day's Range||0.6800 - 0.7397|
|52 Week Range||0.5000 - 1.0900|
|PE Ratio (TTM)||-1.92|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
AVEO Pharmaceuticals, Inc. (AVEO) announced that the phase III study, TIVO-3, evaluating tivozanib in patients with refractory advanced renal cell carcinoma (RCC) has reached its enrollment target
AVEO Pharmaceuticals (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AVEO Pharmaceuticals, Inc. (AVEO) reported a first-quarter 2017 loss of 12 cents per share, narrower than the Zacks Consensus Estimate as well as year-ago loss of 13 cents.